Browse the evidence

Uniaxial accelerometers fail to accurately distinguish energy expenditure during running speeds above 7.8 km/h because the vertical acceleration exceeds the sensor's threshold (1.94 g), leading to a plateau in activity levels despite increasing metabolic cost.

If you use a uniaxial waist accelerometer, be aware that it likely stops distinguishing between different running speeds once you exceed ~7.8 km/h (approx. 4.8 mph). The sensor saturates, so it will not accurately reflect the increased energy cost of vigorous running. It is more reliable for walking and moderate activities.

Human immune function exhibits significant seasonal variation, with a pro-inflammatory transcriptomic profile and increased circulating levels of risk biomarkers (sIL-6R, CRP) during winter months in temperate climates.

If you live in a temperate climate, your immune system is biologically wired to be more inflammatory in winter. This is an evolutionary adaptation, not just a reaction to germs. Be aware that this internal shift may increase your baseline risk for inflammatory conditions during winter months, regardless of your lifestyle choices.

The cellular composition of peripheral blood changes seasonally, with white blood cell counts and specific lineages (lymphocytes, monocytes, neutrophils) varying significantly by season in temperate regions.

Your blood cell counts are not static; they fluctuate with the seasons. This is a normal physiological variation, not necessarily a sign of disease, but it contributes to the overall seasonal immune profile.

Seasonal gene expression patterns in the immune system are inverted between the Northern and Southern hemispheres, indicating a photoperiod-driven circannual rhythm.

If you move from the Northern to the Southern hemisphere (or vice versa), your immune system's seasonal gene expression will invert to match the new local season, suggesting your body tracks daylight length to regulate immunity.

CPAP therapy normalizes subjective daytime sleepiness (measured by ESS) in a dose-dependent manner, but fails to normalize objective vigilance (MWT) or quality of life (FOSQ) in a substantial proportion of patients even with optimal adherence.

If you have moderate to severe sleep apnea, using CPAP for at least 7 hours a night significantly improves how sleepy you feel during the day. However, do not assume you will feel 100% normal or have perfect energy levels just because you are using the machine correctly. About 1 in 5 to 1 in 3 users still have residual sleepiness or quality of life issues despite perfect adherence. If this happens to you, do not stop using the CPAP. Instead, consult your doctor to check for other causes of fatigue, such as depression, obesity, or other sleep disorders.

Roux-en-Y gastric bypass (RYGB) surgery improves glucose homeostasis and reduces appetite largely through altered gut hormonal milieus (increased GLP-1/PYY, decreased ghrelin) rather than solely through caloric restriction or malabsorption.

Bariatric surgery like RYGB works not just by making your stomach smaller, but by changing the hormones your gut releases, which helps fix diabetes and reduces hunger signals to your brain.

Carriers of the TM6SF2 E167K genetic variant have a significantly reduced risk of cardiovascular events (myocardial infarction and stroke) and carotid atherosclerosis due to lower circulating levels of atherogenic lipoproteins.

If you carry the TM6SF2 E167K variant, your body naturally keeps blood cholesterol lower by storing more fat in your liver. This genetic trait significantly lowers your risk of heart attacks and strokes, even if you have fatty liver. You should prioritize cardiovascular health monitoring, but the genetic risk for heart disease is actually reduced.

In human abdominal (visceral) obesity, circulating levels of the endocannabinoid 2-AG are significantly elevated and correlate with visceral fat mass, serving as a critical correlate of peripheral endocannabinoid system dysregulation.

If you have abdominal obesity, your body likely has higher levels of 2-AG, a lipid messenger that promotes fat storage and insulin resistance. This is not just 'being overweight'; it is a specific hormonal state driven by visceral fat. Addressing visceral fat accumulation is key to correcting this dysregulation.

In visceral adipose tissue of obese individuals, the expression of the CB1 receptor and the degrading enzyme FAAH is downregulated, creating a negative-feedback loop that sustains high local endocannabinoid activity.

Your visceral fat tissue actively downregulates the enzymes that break down fat-storing signals (like FAAH) and receptors (CB1). This creates a self-reinforcing cycle where high fat levels lead to hormonal changes that promote further fat storage. Breaking this cycle requires addressing the visceral fat itself.

Elevated circulating 2-AG levels in visceral obesity are negatively correlated with insulin sensitivity, as measured by glucose infusion rate during euglycemic-hyperinsulinemic clamp, independent of total body fat mass.

High levels of 2-AG in your blood are linked to insulin resistance, meaning your body struggles to use insulin effectively to manage blood sugar. This link exists even when you account for how much fat you have, suggesting 2-AG plays a direct role in metabolic dysfunction.

Higher fecal short-chain fatty acid (SCFA) levels are associated with gut dysbiosis, increased gut permeability, obesity, and cardiometabolic risk factors, suggesting that high fecal SCFA excretion reflects inefficient absorption rather than health benefits.

High levels of short-chain fatty acids in your stool might not be a sign of a healthy gut; this study links them to obesity and metabolic risks. This suggests your body might not be absorbing these beneficial compounds efficiently. Focus on overall gut health and diversity rather than just maximizing SCFA production, as poor absorption (high fecal SCFA) is a marker of metabolic dysregulation.

Growth hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) supplementation improves cardiovascular health by attenuating mitochondrial oxidative stress, upregulating antioxidant enzymes, and preserving endothelial progenitor cell function.

Maintaining healthy levels of Growth Hormone and IGF-1 is critical for heart health in aging. Deficiency in these hormones is linked to premature atherosclerosis and higher cardiovascular mortality. While extremely high levels may have other risks, low-normal levels are associated with increased heart disease risk, suggesting that preserving this hormonal axis is beneficial for vascular longevity.

High-intensity interval exercise increases cerebral angiogenesis and VEGFA levels via the lactate receptor HCAR1, a mechanism absent in skeletal muscle.

To maximize brain blood vessel growth, you likely need to exercise at high intensities that elevate blood lactate levels, as this triggers a specific receptor (HCAR1) that low-intensity exercise may not sufficiently activate.

Sleep deprivation accelerates the progression of neurodegenerative diseases, particularly Alzheimer's, by impairing the glymphatic clearance of beta-amyloid (Aβ) and increasing neuroinflammation.

Prioritize 7-8 hours of sleep to support your brain's waste clearance system. Sleep deprivation impairs the glymphatic system, leading to the accumulation of beta-amyloid plaques associated with Alzheimer's disease. Consistent, adequate sleep is a critical protective factor for long-term cognitive health.

BMAL1 is a necessary transcription factor for adipogenesis; its absence prevents lipid accumulation and expression of key adipocyte genes (PPARγ2, aP2), while its restoration or overexpression promotes lipogenesis and lipid synthesis.

This research highlights that your body's internal clock (circadian rhythm) and genetic factors play a crucial role in how fat cells develop and store energy. While you cannot change your genes, maintaining a regular sleep schedule and avoiding late-night eating might support healthy fat metabolism by aligning with your body's natural BMAL1 rhythms.

Mitochondrial fatty acid oxidation capacity in NAFLD is impaired or maximally activated, leading to compensatory up-regulation of peroxisomal and microsomal oxidation pathways.

The liver tries to burn off excess fat through multiple pathways (mitochondrial, peroxisomal, microsomal). In NAFLD, mitochondrial entry (CPT1a) is restricted, but other oxidation pathways are up-regulated to compensate. This suggests that simply 'boosting mitochondrial function' might not address the root cause if the regulatory bottleneck (CPT1a/SREBP-1c) remains.

Rosiglitazone reduces liver fat content and increases insulin clearance in patients with type 2 diabetes, whereas metformin improves hepatic insulin sensitivity without altering liver fat.

For patients with type 2 diabetes, rosiglitazone (a PPAR-gamma agonist) significantly reduces liver fat and improves how the liver clears insulin, leading to better peripheral glucose uptake. Metformin, while effective for lowering blood sugar and improving hepatic insulin sensitivity, does not reduce liver fat. This suggests that the choice of medication may depend on whether reducing liver fat is a primary therapeutic goal.

Rosiglitazone increases insulin clearance in patients with type 2 diabetes, which contributes to the decrease in fasting serum insulin concentrations.

Rosiglitazone helps the liver clear insulin more efficiently, which lowers fasting insulin levels. This is linked to the drug's ability to reduce liver fat and increase adiponectin. Metformin does not have this effect on insulin clearance.

Rosiglitazone increases serum adiponectin concentrations and adipose tissue gene expression of PPAR-gamma, adiponectin, and lipoprotein lipase, whereas metformin does not.

Rosiglitazone significantly boosts adiponectin, a hormone that improves insulin sensitivity and reduces liver fat. Metformin does not have this effect on adiponectin levels.

Excess weight gain causes hypertension primarily through activation of the sympathetic nervous system (SNS), mediated by leptin and melanocortin receptors, leading to increased renal sodium reabsorption and impaired pressure natriuresis.

If you are obese, your high blood pressure is likely driven by your nervous system being overactive due to hormonal signals from fat cells. Losing weight helps, but understanding that your body's 'thermostat' for blood pressure is set too high by these signals is key. Treatments that block these signals (like certain blood pressure meds) are often more effective in obese individuals.

Obesity induces 'selective leptin resistance' where the appetite-suppressing effects of leptin are blunted, but the blood pressure-raising effects (via SNS activation) remain intact.

Your body produces high levels of leptin, but your brain ignores its 'stop eating' command. However, it still listens to leptin's command to raise blood pressure. This mismatch makes losing weight and controlling blood pressure harder. Treatments that mimic or bypass leptin signaling (like GLP-1 agonists) may help by addressing these pathways.

Activation of the central melanocortin 4 receptor (MC4R) is necessary for obesity to increase sympathetic nervous system activity and arterial pressure.

Blocking the MC4 receptor lowers blood pressure in obese individuals, even if they gain weight. This suggests that targeting this specific brain pathway is a viable strategy for treating obesity-related hypertension.

Chronic systemic inflammation impairs muscle homeostasis and myogenesis by activating catabolic pathways (proteasome/autophagy) and inhibiting anabolic signaling (IGF-1/Akt/mTOR), leading to muscle atrophy.

If you are dealing with a chronic inflammatory condition, muscle loss is driven by biological signals (cytokines) that break down muscle and block growth. Standard advice might focus only on eating more protein, but addressing the underlying inflammation (through medical treatment or specific lifestyle interventions like exercise which can correct cytokine levels) is crucial to preserving muscle mass.

Chronic inflammation impairs muscle regeneration by disrupting the transition of satellite cells from proliferation to differentiation, often leading to fibrosis and reduced muscle quality.

When you injure your muscle, some inflammation is necessary for it to heal properly. Chronic, long-term inflammation (from disease or overuse) is what stops repair and causes scarring. Focus on treating the underlying chronic condition rather than just masking acute pain with anti-inflammatories, as the body needs the initial inflammatory signal to start regeneration.